On October 15, 2026 Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, reported that three abstracts, including an oral presentation, will be featured at the 2026 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place November 4-8 in Phoenix, AZ.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The three accepted abstracts focus on preclinical data demonstrating how Ankyra’s anchored immunotherapy platform can be applied to multiple immune-modulating agonists, including CD40, CD28, CD137 (4-1BB), and IL-2/IL-15, to precisely target localized solid tumors and anchor powerful cancer-fighting therapeutics in the tumor microenvironment to minimize side effects and maximize therapeutic effect. These findings build on the company’s ongoing Phase 1 study of tolododekin alfa, a first-in-class IL-12-anchored immunotherapy that has demonstrated durable tumor retention, promising clinical activity, and a favorable safety profile. Together, the data highlight the versatility of Ankyra’s anchored immunotherapy platform and the potential to realize the promise of therapeutics previously shelved due to toxicity concerns.
"We look forward to presenting new data from our anchored immunotherapy platform and pipeline, including our CD40, CD28, CD137, and CD122 (IL-2/15Rβ) multi-agonists," said Howard Kaufman, President and CEO of Ankyra Therapeutics. "Our next-generation local immunotherapies have the potential to completely change the cancer treatment continuum and our priority is now advancing them from the lab to the clinic to help address unmet needs for people with cancer."
Presentation details:
Title: Anchored immunotherapy with CD137 (4-1BB) and CD122 (IL-2/15Rβ) multi-agonists induce monotherapy anti-tumor immunity and abscopal responses without systemic toxicity
Type: Oral Presentation
Session: Cytokine Engineering and Clinical Translation
Abstract: 1061
Date / time: Friday, November 6, 2026 – 5:15-5:25pm MT
Lead author: Robert G. Newman, PhD, Ankyra Therapeutics
Title: Safety and efficacy of ANK-302, an alum anchored CD28 and IL-2 bi-agonist in preclinical tumor models
Type: Poster Session
Session: Novel Single-Agent Immunotherapies
Abstract: 1067
Date: Friday, November 6, 2026
Lead author: Lisa Sturla, PhD, Ankyra Therapeutics
Title: Alum-anchored CD40–IL-2 multi-agonist (ANK-301) promotes local and abscopal anti-tumor immunity without systemic toxicity
Type: Poster Session
Session: Immuno-Engineering
Abstract: 930
Date: Saturday, November 7, 2026
Lead author: Kanika Jain, PhD, Ankyra Therapeutics
(Press release, Ankyra Therapeutics, OCT 15, 2026, View Source [SID1234673505])